Patents by Inventor John Edward Tellew

John Edward Tellew has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS
    Publication number: 20210187033
    Abstract: The present invention relates to compounds and compositions for expanding the number of CD34+ cells for transplantation. The invention further relates to a cell population comprising expanded hematopoietic stem cells (HSCs) and its use in autologous or allogeneic transplantation for the treatment of patients with inherited immunodeficient and autoimmune diseases and diverse hematopoietic disorders to reconstitute the hematopoietic cell lineages and immune system defense.
    Type: Application
    Filed: November 6, 2020
    Publication date: June 24, 2021
    Inventors: Anthony Edward Boitano, Michael Cooke, Shifeng Pan, Peter G. Schultz, John Edward Tellew, Yongqin Wan, Xing Wang
  • Pyrazolo[1,5-alpha]pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
    Patent number: 7879862
    Abstract: CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals. The CRF receptor antagonists of this invention have the following structure: (I); and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R1, R2a, R2b, Y, Het, n, o, R6, Ar and R7 are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.
    Type: Grant
    Filed: October 19, 2005
    Date of Patent: February 1, 2011
    Assignee: SmithKline Beecham (Cork) Limited
    Inventors: Marion Lanier, John Edward Tellew, John P. Williams
  • CRF receptor antagonists and methods relating thereto
    Patent number: 7652035
    Abstract: CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals, such as stroke. The CRF receptor antagonists of this invention have the following structure: and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R1, R2, n, R5, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonists in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.
    Type: Grant
    Filed: October 17, 2005
    Date of Patent: January 26, 2010
    Assignees: Neurocrine Bioscience, Inc., SB Cork
    Inventors: Marion Lanier, Manisha Moorjani, John Edward Tellew, John P. Williams
  • Pyrazolo[1,5-Alpha]Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists
    Publication number: 20080194589
    Abstract: CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals. The CRF receptor antagonists of this invention have the following structure: (I); and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R1, R2a, R2b, Y, Het, n, o, R6, Ar and R7 are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.
    Type: Application
    Filed: October 19, 2005
    Publication date: August 14, 2008
    Applicant: NEUROCRINE BIOSCIENCES, INC.
    Inventors: Marion Lanier, Zhiyong Luo, Manisha Moorjani, John Edward Tellew, John P. Williams, Xiaohu Zhang